OakChart

Vor Biopharma Inc

VORHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 11:23 AM ET

20.10+0.54 (2.75%)
2026-11-11 17:24 CET
Market cap
1,201.65 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
1,353.74 USD m
Free cash flow, TTM
-119.68 USD m
EPS diluted, TTM
36.78
P/E
0.55
Compare

Price

VOR against its 20, 50 and 200-day averages
2050200miss
15.0020.0025.004.1M8.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VORclose 20.1020-day 19.3550-day 20.20200-day 17.4820.1052w high

22.7% under the 52-week high of 26.00 on 8 Sep 2026. 52-week low 6.50 on 20 Nov 2025. Last 15 sessions, 22.8% high to low

Profile

VOR
52-week range, 70% of the way up
6.5026.00

Vor Biopharma, Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. It is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

IndexRUT
Employees76
IPOFeb 05, 2021
Beta1.84
ATR, 14d1.21
Rel volume0.22
Short float22.28%
Insider own45.18%
Inst own60.34%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.23B
Enterprise Value756.01M
Income1.35B
Sales0.00M
Book/sh-2.23
Cash/sh7.84
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees76
IPOFeb 05, 2021

Ratios

P/E0.55
Forward P/E-
PEG-
P/S-
P/B-
P/C2.56
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio13.50
Current Ratio13.50
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)36.78
EPS next Y-3.99
EPS next Q-0.99
EPS this Y88.53%
EPS next Y50.68%
EPS next 5Y61.11%
EPS past 3/5Y-14.82% -21.58%
Sales past 3/5Y- -
EPS Y/Y TTM109.51%
Sales Y/Y TTM-
EPS Q/Q98.81%
Sales Q/Q-
EarningsOct 30 BMO
EPS/Sales Surpr.-34.73% -

Ownership

Insider Own45.18%
Insider Trans-0.00%
Inst Own60.34%
Inst Trans18.98%
ROA402.57%
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA203.84%
SMA50-0.48%
SMA20015.00%
Trades-

Technical

Shs Outstand61.43M
Shs Float33.68M
Short Float22.28%
Short Ratio8.01
Short Interest7.50M
52W High26.00 -22.70%
52W Low6.50 209.21%
Volatility6.72% 6.49%
ATR (14)1.21
RSI (14)52.90
Beta1.84
Rel Volume0.22
Avg Volume937.07K
Volume67,798

Performance

Perf Week-0.11%
Perf Month5.45%
Perf Quarter-13.70%
Perf Half Y26.33%
Perf YTD53.66%
Perf Year104.26%
Perf 3Y-42.90%
Perf 5Y-94.00%
Perf 10Y-
Recom1.30
Target Price39.00
Prev Close19.56
Price20.10
Change %2.75%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 21, 2026InitiatedWWilliam BlairOutperform
Mar 30, 2026InitiatedJJefferiesBuy$50+148.8%
Mar 19, 2026InitiatedWWells FargoOverweight$30+49.3%
Jan 09, 2026InitiatedCCitigroupBuy$50+148.8%
Dec 17, 2025InitiatedTTD CowenBuy
Dec 09, 2025InitiatedJJP MorganOverweight$43+113.9%
Nov 25, 2025ResumedWWedbushNeutral$9-55.2%
Oct 15, 2025UpgradeRRobert W. BairdNeutral → Outperform$64+218.4%
Sep 24, 2025UpgradeSStifelHold → Buy$55+173.6%
Jun 30, 2025UpgradeHH.C. WainwrightNeutral → Buy$3-85.1%

Peers

Mkt cap
TickerCompanyMkt cap
VERAVera Therapeutics Inc2.19B
VRTXVertex Pharmaceuticals Inc136.99B
ARGXArgen X SE ADR61.17B
AUPHAurinia Pharmaceuticals Inc2.14B
ZBIOZenas Biopharma Inc1.97B
IMVTImmunovant Inc7.65B
DNTHDianthus Therapeutics Inc5.04B
KYTXKyverna Therapeutics Inc322.14M
TVTXTravere Therapeutics Inc4.94B
CABACabaletta Bio Inc305.24M

Insider trading

14 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
RA CAPITAL MANAGEMENT, L.P.10% OwnerOct 02 '26Option Exercise12.805006,400500Oct 05 06:52 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerAug 24 '26Option Exercise3.741,5005,6041,500Aug 26 06:28 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerJul 16 '26Sale19.752134,2074,501,882Jul 21 04:54 PM
RA CAPITAL MANAGEMENT, L.P.DirectorApr 22 '26Sale15.77165,1502,604,4162,402,095Apr 24 06:12 PM
RA CAPITAL MANAGEMENT, L.P.DirectorApr 17 '26Sale16.28458,4117,462,9312,739,208Apr 21 07:04 PM
RA CAPITAL MANAGEMENT, L.P.DirectorApr 20 '26Sale15.77171,9632,711,8572,567,245Apr 21 07:04 PM
RA CAPITAL MANAGEMENT, L.P.DirectorApr 13 '26Sale16.15530,6108,569,3523,404,998Apr 15 05:29 PM
RA CAPITAL MANAGEMENT, L.P.DirectorApr 14 '26Sale15.97153,7352,455,1483,251,263Apr 15 05:29 PM
RA CAPITAL MANAGEMENT, L.P.DirectorApr 15 '26Sale16.0153,644858,8403,197,619Apr 15 05:29 PM
RA CAPITAL MANAGEMENT, L.P.DirectorApr 08 '26Sale16.48484,1047,977,7864,071,637Apr 10 06:23 PM
RA CAPITAL MANAGEMENT, L.P.DirectorApr 09 '26Sale16.59135,2012,242,9853,936,436Apr 10 06:23 PM
RA CAPITAL MANAGEMENT, L.P.DirectorApr 10 '26Sale15.7582813,0413,935,608Apr 10 06:23 PM
RA CAPITAL MANAGEMENT, L.P.DirectorApr 06 '26Sale16.59589,2579,777,8984,555,741Apr 06 06:51 PM
RA CAPITAL MANAGEMENT, L.P.DirectorApr 02 '26Sale18.23260,0004,741,0665,144,998Apr 06 06:51 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWCiShares Micro-Cap ETFAUM: 1.22B
IWNiShares Russell 2000 Value ETFAUM: 14.10B

News

latest 14 of 206
  • Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
  • Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.26%
  • Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -5.88%
  • Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy (GlobeNewswire)
  • Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Loading…
  • Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis (GlobeNewswire)
  • Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis (GlobeNewswire)
  • Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Vor Bio To Participate in Upcoming September Conferences (GlobeNewswire)
  • Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Vor Bio Appoints David Zaccardelli to Board of Directors (GlobeNewswire)
  • Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.96%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-30-1.450-1.076-1.4500.000.0010
2026Q22026-08-11-1.160-0.704-1.1570.000.009
2026Q12026-05-07-5.109-0.781-5.1050.000.009
2025Q42026-03-3088.74015.67544.4950.000.007
2025Q32025-11-13-121.63-3.453-121.630.000.004
2025Q22025-08-07-251.23-8.767-251.240.000.005
2025Q12025-05-08-5.000-5.258-5.2050.000.007
2024Q42025-03-20-8.800-5.714-8.7790.000.007
2024Q32024-11-07-8.000-8.044-8.0500.000.009
2024Q22024-08-08-8.200-8.356-8.1520.000.009
2024Q12024-05-09-9.000-7.556-9.0560.000.009
2023Q42024-03-20-7.800-10.058-7.7360.000.009
2023Q32023-11-07-9.800-9.356-9.8180.000.009
2023Q22023-08-10-9.000-8.426-8.9450.000.009
2023Q12023-05-11-8.600-7.476-8.5820.000.008
2022Q42023-03-23-10.600-11.982-10.2840.000.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-4,303-882.53-26.5360.000.00
2021FY-42.000-47.942-37.7280.000.00
2022FY-46.600-46.168-46.5690.000.00
2023FY-35.000-37.622-35.0820.000.00
2024FY-34.000-28.743-34.0330.000.00
2025FY-70.500-69.754-70.5000.000.00
2026FY--8.084--0.00
2027FY--3.987--0.00
2028FY--4.146--28.90
2029FY--3.126--173.32
2030FY--1.026--472.57

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-306000.000.000.00
2026Q4S2026-08-205000.000.000.00
2026Q4S2026-08-116000.000.000.00
2026Q4S2026-05-126000.000.000.00
2026Q4S2026-05-075000.000.000.00
2026Q4S2026-04-145000.000.000.00
2026Q4S2026-04-024000.000.000.00
2026Q4S2026-03-303000.000.000.00
2026Q4S2026-03-184000.000.000.00
2026Q4S2025-12-163000.000.000.00
2026Q4S2025-11-242000.000.000.00
2026Q4S2025-11-201000.000.000.00
2026Q4S2025-11-142000.000.000.00
2026Q4S2025-11-112000.000.000.00

Estimate history

EPS, annual-2.237-6.795-26.536-37.728-46.569-35.082-34.033-70.50236.7797
Period20182019202020212022202320242025TTM
EPS, quarterly-8.05-8.779-5.205-251.241-121.62744.495-5.105-1.157-1.453
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.8561.8561.8561.8593.33.3956.23938.7261.43
Period20182019202020212022202320242025MRQ
Shares, quarterly3.4336.2396.2436.2829.02738.7254.18654.45661.43
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.132.893.533.498.964.451.390.090.02
Gross Profit-0.13-2.89-3.53-3.49-8.96-4.45-1.39-0.09-0.02
Selling, General and Administrative Excl. Other177.29368.75117.66122.5484.4664.5741.9810.332.84
Research and Development97.24321.5393.3194.3164.5547.5331.626.202.43
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-177.42-371.64-121.19-126.04-93.42-69.02-43.37-10.42-2.86
Interest Expense0.000.000.000.000.000.000.000.611.00
Unusual Expense-1,515.47334.360.000.000.000.000.00-0.030.29
Net Income Before Taxes1,353.74-695.98-116.91-117.86-92.09-68.90-43.34-10.84-4.15
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income1,353.74-695.98-116.91-117.86-92.09-68.90-43.34-10.84-4.15
Net Income From Continuing Operations1,353.74-695.98-116.91-117.86-92.09-68.90-43.34-10.84-4.15
Net Income1,353.74-695.98-116.91-117.86-92.09-70.13-49.26-12.61-4.15
EPS (Recurring)4.91-46.79-34.03-35.08-46.57-37.73-26.54-6.81-2.13
EPS (Basic, Before Extraordinaries)36.78-70.50-34.03-35.08-46.57-37.73-26.54-6.80-2.24
EPS (Diluted)36.78-70.50-34.03-35.08-46.57-37.73-26.54-6.80-2.24
EBITDA-177.29-368.75-117.66-122.54-84.46-64.57-41.98-10.33-2.84
Non-Operating Income (Expense)15.6810.024.278.171.320.120.030.150.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense35.3218.919.8513.3610.704.321.340.170.12
Price To Earnings Ratio0.530.53-------
Shares Outstanding61.4338.726.243.393.301.861.861.861.86
Market Capitalization1,201.651,201.65138.50152.52255.31431.97440.15--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.040.040.030.020.002.100.820.86
Gross Profit-0.04-0.04-0.03-0.02-0.00-2.10-0.82-0.86
Selling, General and Administrative Excl. Other58.4147.8235.1335.9428.11272.1832.4730.45
Research and Development34.5325.9217.5919.1914.14261.5026.7025.35
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-58.44-47.85-35.16-35.96-28.11-274.28-33.29-31.31
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense32.8919.30188.36-1,756.02790.461,299.920.000.00
Net Income Before Taxes-86.73-62.81-219.591,722.86-812.68-1,573.67-32.49-30.71
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-86.73-62.81-219.591,722.86-812.68-1,573.67-32.49-30.71
Net Income From Continuing Operations-86.73-62.81-219.591,722.86-812.68-1,573.67-32.49-30.71
Net Income-86.73-62.81-219.591,722.86-812.68-1,573.67-32.49-30.71
EPS (Recurring)-1.07-0.91-2.0412.75-38.82-105.97-5.21-8.78
EPS (Basic, Before Extraordinaries)-1.45-1.16-5.1144.50-121.63-251.24-5.21-8.78
EPS (Diluted)-1.45-1.16-5.1144.50-121.63-251.24-5.21-8.78
EBITDA-58.41-47.82-35.13-35.94-28.11-272.18-32.47-30.45
Non-Operating Income (Expense)4.614.343.942.805.880.540.810.60
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.949.408.877.118.031.841.931.71
Price To Earnings Ratio0.53-------
Shares Outstanding61.4354.4654.1938.729.036.286.246.24
Market Capitalization1,201.65997.56740.71286.59333.30203.5589.58138.50

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments455.2191.93137.18230.25207.4748.546.470.93
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets2.904.583.636.716.930.571.070.01
Total Current Assets458.1196.51140.80236.95214.4049.117.540.94
Net Property, Plant & Equipment3.4741.5950.1057.0822.5221.840.730.07
Total Investments and Advances0.172.412.412.412.411.561.560.00
Intangible Assets------0.000.00
Deferred Tax Assets0.8810.1311.70-----
Other Assets2.382.384.812.923.253.400.000.00
Total Assets465.01153.02209.83299.37242.5975.919.831.01
Short Term Debt Incl. Current Port. of LT Debt0.284.213.833.271.840.860.004.46
Accounts Payable5.131.500.811.771.542.360.690.04
Other Current Liabilities19.7612.8910.938.076.776.981.493.28
Total Current Liabilities25.1718.6115.5713.1210.1510.212.197.77
Long Term Debt2.7227.6131.8335.6416.1717.430.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.8810.1311.70-----
Other Liabilities600.550.000.000.000.000.000.000.00
Total Liabilities629.3256.3559.1048.7626.3327.642.197.77
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00107.3425.070.00
Common Equity-164.3196.66150.72250.61216.26-59.06-17.43-6.77
Total Shareholders Equity-164.3196.66150.72250.61216.2648.277.64-6.77
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity-164.3196.66150.72250.61216.2648.277.64-6.77
Total Liabilities & Stockholders Equity465.01153.02209.83299.37242.5975.919.831.01
Book Value Per Share-4.2415.4944.4075.95116.35-31.82-9.39-3.65
Tangible Book Value Per Share-4.2415.4944.4075.95116.35-31.82-9.39-3.65
Full-Time Employees7615916813313588--
Price to Book Ratio-8.761.430.871.612.001.89--
Return on Assets-225.23-64.44-46.29-33.99-43.26-101.10-200.11-
Return on Equity--94.52-58.74-39.45-52.09-155.02-2,483.16-
Return on Invested Capital--94.07-64.56-32.17-29.64-65.96-141.87-
Quick Ratio18.205.199.0418.0621.124.813.450.12
Current Ratio18.205.199.0418.0621.124.813.450.12

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income1,353.74-695.98-116.91-117.86-92.09-68.90-43.34-10.84-4.15
Depreciation0.132.893.533.498.964.451.390.090.02
Other Funds (Non Cash)-1,481.13540.1713.7213.4310.684.491.340.751.41
Funds from Operations-127.27-152.92-99.67-100.94-72.45-59.96-40.61-10.00-2.72
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital8.1010.210.010.65-12.69-9.194.320.140.06
Cash from Operating Activities-119.17-142.71-99.66-100.29-85.14-69.14-36.29-9.86-2.66
Capital Expenditures-0.51-0.94-0.23-1.07-8.46-3.89-4.16-0.750.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.800.000.000.000.000.000.000.00
Purchase or Sale of Investments-393.02-48.6697.0972.08-85.63-87.760.000.000.00
Purchase of Investments-526.35-53.66-9.91-74.92-123.19-87.760.000.000.00
Sale Or Maturity of Investments133.335.00107.00147.0037.560.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-393.53-48.8096.8671.01-94.09-91.65-4.16-0.750.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock431.56504.0653.734.12117.14232.9182.5317.700.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock431.56504.0653.734.12117.14232.9182.5317.700.00
Proceedsfrom Stock Options255.98326.8853.503.86115.97232.3682.2717.690.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.002.46
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.34-0.25-0.33-1.190.000.000.000.000.00
Other Financing Activities Uses-0.34-0.25-0.33-1.190.000.000.000.000.00
Cash from Financing Activities431.21503.8153.392.94117.14232.9182.5317.702.46
Net Change in Cash-81.48312.2950.59-26.35-62.0972.1242.077.10-0.20
Free Cash Flow-119.68-143.65-99.89-101.36-93.61-73.04-40.45-10.60-2.66
Preferred Dividends (Cash Flow)-0.000.000.000.00---0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments481.55466.13491.52455.21170.46202.98
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets8.978.989.252.902.021.95
Total Current Assets490.52475.11500.78458.11172.49204.93
Net Property, Plant & Equipment3.233.373.393.473.310.02
Total Investments and Advances0.170.170.170.170.170.00
Deferred Tax Assets---0.88--
Other Assets2.392.412.412.380.270.42
Total Assets496.31481.05506.75465.01176.24205.37
Short Term Debt Incl. Current Port. of LT Debt0.370.340.310.280.250.00
Accounts Payable5.614.001.045.130.890.67
Other Current Liabilities30.3620.4814.7319.7617.7058.10
Total Current Liabilities36.3424.8116.0825.1718.8458.77
Long Term Debt2.442.542.632.722.810.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.88--
Other Liabilities594.70653.89638.46600.552,380.081,652.30
Total Liabilities633.49681.25657.17629.322,401.721,711.07
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-137.17-200.20-150.42-164.31-2,225.49-1,505.70
Total Shareholders Equity-137.17-200.20-150.42-164.31-2,225.49-1,505.70
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-137.17-200.20-150.42-164.31-2,225.49-1,505.70
Total Liabilities & Stockholders Equity496.31481.05506.75465.01176.24205.37
Book Value Per Share-2.23-3.68-2.78-4.24-246.54-239.67
Tangible Book Value Per Share-2.23-3.68-2.78-4.24-246.54-239.67
Full-Time Employees---76--
Price to Book Ratio-8.76-6.63-4.20-0.05-0.20-0.14
Return on Assets402.57182.91-286.69-225.23-1,676.47-959.44
Quick Ratio13.5019.1531.1518.209.163.49
Current Ratio13.5019.1531.1518.209.163.49

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-86.73-62.81-219.591,722.86-812.68-1,573.67
Depreciation0.040.040.030.020.002.04
Other Funds (Non Cash)42.4828.38196.85-1,748.84753.961,531.82
Funds from Operations-44.21-34.39-22.71-25.96-58.72-39.81
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital11.469.01-15.543.165.064.63
Cash from Operating Activities-32.75-25.38-38.25-22.80-53.66-35.18
Capital Expenditures-0.03-0.12-0.05-0.31-0.24-0.15
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.80
Purchase or Sale of Investments-44.76-36.41-263.19-48.660.00-0.00
Purchase of Investments-117.19-79.00-276.50-53.660.000.00
Sale Or Maturity of Investments72.4342.5913.315.000.00-0.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-44.78-36.53-263.24-48.97-0.240.65
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock48.84-0.1074.87307.9521.57175.10
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock48.84-0.1074.87307.9521.57175.10
Proceedsfrom Stock Options123.39-75.1174.87132.8219.61175.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.19-0.00-0.00-0.15-0.02-0.03
Other Financing Activities Uses-0.19-0.00-0.00-0.15-0.02-0.03
Cash from Financing Activities48.65-0.1174.87307.8021.55175.06
Net Change in Cash-28.88-62.02-226.61236.02-32.36140.53
Free Cash Flow-32.77-25.50-38.29-23.11-53.91-35.34

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3022.28%7.5M33.7M949.61K
2026-10-1522.96%7.4M32.4M967.66K
2026-09-3024.10%7.8M32.4M1.10M
2026-09-1524.37%7.9M32.4M1.13M
2026-08-3123.64%7.7M32.4M1.15M
2026-08-1422.67%7.4M32.4M1.16M
2026-07-3125.12%7.3M28.9M1.18M
2026-07-1525.25%7.3M28.9M1.21M
2026-06-3026.82%7.7M28.9M1.18M
2026-06-1520.61%6.0M28.9M1.06M
2026-05-2916.69%4.8M28.9M1.03M
2026-05-1512.60%4.6M36.5M1.01M
2026-04-3014.45%5.0M34.3M993.56K
2026-04-1513.71%4.7M34.3M992.09K
2026-03-3115.55%5.7M36.6M960.31K
2026-03-1310.98%3.4M31.1M984.10K
2026-02-2710.89%3.4M31.1M1.75M
2026-02-1310.22%3.2M31.1M1.76M
2026-01-3014.71%2.6M17.4M1.85M
2026-01-1512.61%2.2M17.4M1.74M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5016.0018.400.0012.7340.000.000.995-0.0180.000
call5.0013.5016.100.008.9330.000.000.959-0.1240.003
call7.5011.0013.400.005.9910.000.000.938-0.1250.004
call10.008.3012.0010.406.3981380.000.913-0.1210.005
call12.506.608.7012.893.79538.000.000.882-0.1130.006
call15.002.507.006.703.7851.000.000.834-0.0990.008
call17.502.004.902.152.9612630.000.730-0.1100.010
call20.000.404.901.103.92440.000.000.601-0.2130.012
call22.500.051.151.581.6038.000.000.375-0.1070.012
call25.000.000.950.051.9376.000.000.288-0.1160.011
call30.000.000.750.582.49198.000.000.203-0.1230.009
call35.000.000.750.303.0889.000.000.177-0.1380.008
put2.500.000.050.000.0000.000.000.0000.0000.000
put5.000.004.500.007.9900.000.00-0.041-0.1230.003
put7.500.004.900.005.8080.000.00-0.062-0.1240.004
put10.000.004.500.004.3510.000.00-0.087-0.1200.005
put12.500.000.750.003.1370.000.00-0.123-0.1090.006
put15.000.000.750.354.4130.000.00-0.233-0.2200.010
put17.500.001.150.051.8671300.00-0.272-0.1070.010
put20.000.003.001.902.43766.000.00-0.399-0.2110.012
put22.500.904.505.502.37635.000.00-0.626-0.1050.012
put25.003.007.505.403.33387.000.00-0.713-0.1140.011
put30.008.0012.508.604.16710.000.00-0.797-0.1200.009
put35.0014.1016.5012.703.7295.000.00-0.823-0.1340.008

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-10-30424B5SEC
2026-10-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-09-04S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-07SCHEDULE 13G/ASEC
2026-08-06SCHEDULE 13GSEC
2026-07-30SCHEDULE 13GSEC
2026-07-21SCHEDULE 13D/ASEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-093Initial statement of beneficial ownership of securities2026-07-07SEC
2026-07-078-KCurrent report2026-07-06SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-128-KCurrent report2026-06-11SEC
2026-06-088-KCurrent report2026-06-08SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-07004.21K1
2026-060000
2026-050000
2026-040049.42M11
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC11.42%
TCG Crossover Management, LLC10.47%
FCPM III SERVICES B.V.7.60%
BlackRock, Inc.6.40%
Venrock Adviser, LLC5.61%
STATE STREET CORP4.83%
Frazier Life Sciences Management, L.P.4.69%
RA CAPITAL MANAGEMENT, L.P.4.43%
VANGUARD CAPITAL MANAGEMENT LLC3.85%
Caligan Partners LP3.55%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.24%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.86%
Select Biotechnology Portfolio2.37%
Fidelity Small Cap Growth Fund2.34%
iShares Russell 2000 ETF1.76%
Fidelity Small Cap Growth K6 Fund1.20%
Fidelity Stock Selector Small Cap Fund1.09%
VANGUARD EXTENDED MARKET INDEX FUND0.91%
Fidelity Small Cap Index Fund0.82%
Fidelity Series Small Cap Opportunities Fund0.74%

OakChart. VOR. Cached 15 minutes.